Abstract
Angiogenic factors can be used when pre-eclampsia is suspected.
Pre-eclampsia complicates 7% of pregnancies. The heterogeneity of the syndrome makes it difficult to assess its development and complications, and the current models have low predictive values. Studies indicate a significant difference in the levels of the angiogenic factors: placental growth factor (PlGF) and soluble fms-like tyrosin kinase 1 (sFlt-1), as well as the sFlt-1-PlGF ratio in women with preeclampsia compared to women without pre-eclampsia. These angiogenic factors can also be used to help find the women at risk for complications. However, before implementing PlGF and sFlt-1-PlGF ratio in the diagnosis and risk assessment, establishment and further validation of cut-offs are needed.
Pre-eclampsia complicates 7% of pregnancies. The heterogeneity of the syndrome makes it difficult to assess its development and complications, and the current models have low predictive values. Studies indicate a significant difference in the levels of the angiogenic factors: placental growth factor (PlGF) and soluble fms-like tyrosin kinase 1 (sFlt-1), as well as the sFlt-1-PlGF ratio in women with preeclampsia compared to women without pre-eclampsia. These angiogenic factors can also be used to help find the women at risk for complications. However, before implementing PlGF and sFlt-1-PlGF ratio in the diagnosis and risk assessment, establishment and further validation of cut-offs are needed.
| Bidragets oversatte titel | Angiogenic factors can be used when pre-eclampsia is suspected |
|---|---|
| Originalsprog | Dansk |
| Artikelnummer | V11140638 |
| Tidsskrift | Ugeskrift for Laeger |
| Vol/bind | 178 |
| Udgave nummer | 2 |
| Sider (fra-til) | 164-69 |
| Antal sider | 6 |
| ISSN | 0041-5782 |
| Status | Udgivet - 25 maj 2015 |